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Abstract: Background: Huntington’s disease (HD) is a rare and fatal inherited genetic disorder characterized
by progressive motor, cognitive, and behavioral impairment. It leads to premature death, but data regarding
advanced-stage disease are scarce. We sought to determine HD-associated survival, mortality, and causes
and places of death.
Methods: Data from the European HD Network prospective study (REGISTRY) collected from 2001 through
2013 were used, including the Unified Huntington’s Disease Rating Scale and death report forms. Group
comparisons were performed using the t test or the v2 test. Survival analyses were computed through
Kaplan-Meier estimates of median survival. All tests were 2-sided with a significance level of P = 0.05.
Results: In total, 5164 participants were analyzed. The mean age at diagnosis was 49 years, and the mean
age at death was 58 years. At the end of the study period, there were 533 deaths (10.3% of patients). Median
survival was 24 years from diagnosis and 35 years from symptom onset. The most frequent causes of death
were pneumonia (19.5%), other infections (6.9%), and suicide (6.6%). The most frequent places of death were
the hospital (29.8%), the home (23.9%), and nursing houses (19.8%).
Conclusions: Patients with HD tend to die from the same conditions as patients with other neurodegenerative
diseases. However, compared with nonhereditary Parkinson’s disease and Alzheimer’s disease, the median
time from onset to death is longer, and the places of death are distinctive.
Huntington’s disease (HD) is a rare and fatal inherited genetic
disorder caused by a CAG repeat expansion at the IT15 gene
on chromosome 4.1,2 It is characterized by progressive motor,
cognitive, and behavioral impairment, invariably leading to
premature disability, with no disease-modifying treatments
currently available.3 Despite this, the advanced stage of this con-
dition has not been extensively studied, and knowledge about
this phase of the disease would be essential to plan care and
supportive services for individuals with HD and their families4
and to define patient outcomes in clinical studies.
Prognostication,5 advance-directive decision making, antici-
pating end-stage care needs6 and life-prolonging procedures,
and comfort-maximizing and quality-of-life–maximizing
approaches are all essential matters for patients with HD and
their carers. Because the current literature on this topic is lim-
ited and dated, we sought to determine the survival, mortality,
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and causes and places of death of in patients with HD from the
European Huntington’s Disease Network’s (EHDN) prospective
cohort (the REGISTRY study7) and to help contribute to the
improvement of care and clinical management and lessen the
burden of the disease and improve the quality of life of patients
and their families at this late stage in the disease.8
Materials and Methods
Ethical Approval
This study was performed in accordance with the declaration
of Helsinki and was approved by the local ethics committees
for each study site contributing to the REGISTRY study.
All participants gave informed written consent. Participants
who lacked the capacity to consent and minors had consent
given on their behalf as requested by country-specific ethical
standards.
Participants
All participants were part of the EHDN multicenter, Euro-
pean, prospective observational study–REGISTRY.7 Partici-
pants were recruited from 20 countries, although only 17
countries contributed data to our database (Austria, Belgium,
Czech Republic, Denmark, Finland, France, Germany, Italy,
Netherlands, Norway, Poland, Portugal, Russian Federation,
Spain, Sweden, Switzerland, and the United Kingdom).
Although REGISTRY recruited healthy controls, individuals
at risk of HD, those with premanifest HD, and those with
manifest HD, only the latter were included in our study. Par-
ticipants were recruited from local HD clinics, and data collec-
tion followed a standard protocol, including the Unified
Huntington’s Disease Rating Scale (UHDRS),9 using elec-
tronic-based report forms. After consent, participants were
evaluated according to baseline and annual follow-up visits
until study termination or death. EHDN monitors checked
data regularly for completeness and plausibility. For the pur-
pose of this analysis, patients with manifest HD were defined
as those with a CAG-expanded allele of the HD gene and
with a diagnostic confidence level (DCL) of 4.10 In addition,
although included participants had been recruited at the begin-
ning of the study, mortality data were truncated from 2001
through 2013.
Clinical Information
Age at the onset of motor, cognitive, and behavioral symptoms;
sex; and ethnicity from all manifest REGISTRY participants
were extracted from study forms. For individuals who died, data
were also extracted from the REGISTRY death report form,
including age, place, and cause of death. These forms were
completed by trained raters, and data were often gathered from
patients’ families. Although it was optional to include autopsy
information, most participants who died did not undergo this
procedure.
Statistical Analysis
Statistical analysis was performed with SPSS software, version
18 (SPSS, Inc., Chicago, IL) and R software (R Foundation for
Statistical Computing, Vienna, Austria). Descriptive statistics are
presented as mean (standard deviation [SD], minimum–maxi-
mum) for continuous variables and proportions for categorical
variables. Group comparisons were performed using the t test or
the v2 test, respectively. Survival analyses were computed
through Kaplan-Meier estimates of median survival and 95%
confidence intervals (CIs). Sex, the number of CAG repeats,
age of onset, first manifestation, and country were planned to
be tested as covariates. Unfortunately, this was not possible due
to lack of statistical power. All tests were 2-sided with a signifi-
cance level of P = 0.05.
Results
Participants
In total, 5164 participants with manifest HD were analyzed
(men, 49.0%, Caucasians, 98.0%; mean  SD age at diagnosis,
47  12 years [range, 5–86 years]). For detailed descriptions of
the REGISTRY protocol and participants, please refer to publi-
cations by the EHDN7 and Orth et al.,11 respectively. At the
end of the study period, from 2001 to 2013, there were 533
deaths (10.3% of patients). When considering only those who
had died (men, 57.4%; Caucasians, 98.0%), the mean  SD age
at diagnosis was 49  14 years (range, 9–85 years), and the
mean  SD age at death was 58  13 years (range, 16–
93 years). Differences between sex (P < 0.001) and the mean
age at diagnosis (P = 0.03) were observed between those who
had died and those who remained alive at the end of the study
period. Most patients were from the United Kingdom (23.3%),
followed by Germany (17%), Spain (16.3%), Italy (9.4%), and
France (8.7%).
Survival
Median survival was defined as the time after which only 50%
of the participants were still alive. The median survival from
symptom onset to death was 35 years (95% CI, 29.2–
40.8 years) (Fig. 1, left). Survival estimates for sex or other
covariables could not be computed due to lack of statistical
power. The median survival from motor diagnosis to death
was 24 years (95% CI, 20.8–27.2 years) (Fig. 1, right). Again,
survival estimates for sex or other covariables could not be
computed.
Causes of Death
The most frequent cause of death was pneumonia (19.5%), fol-
lowed by other infections (6.9%), suicide (6.6%), cancer (3.4%),
stroke (2.6%), and trauma (0.9%). Other causes were identified
in 36.4% of participants, and the cause of death was undeter-
mined in 23.6% of deaths (Table 1). No significant difference
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was observed in the distribution of causes of death between
countries (P = 0.372) (Table S1).
Places of Death
The most frequent place of death was the hospital (29.8%), fol-
lowed by home (23.9%), nursing houses (19.8%), and hospice
care facilities (3.3%). The place of death was undetermined in
23.1% of deaths (Table 1). No significant difference was
observed in the distribution of places of death between coun-
tries (P = 0.419) (Table S2).
Discussion
To the best of our knowledge, this is the first report of survival,
mortality, causes and places of death in patients with manifest
HD from an international, multicenter prospective study. In
Europe, individuals with HD die a median of 35 years after
symptoms onset, and 24 years after formal diagnosis, at a mean
age of 58 years (see Fig. 1). In addition, death occurs most
frequently from pneumonia and other infections, and the most
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Figure 1 The survival of patients with manifest Huntington’s disease included in the REGISTRY study, (Left) after symptom onset and
(Right) after the motor diagnosis.
TABLE 1 Causes and places of death among patients with manifest Huntington’s disease included in the REGISTRY study
Variable No. of patients
(%)
Age at death:




Mean  SD, y
Symptom duration:
Mean  SD, y
Causes of death
Pneumonia 104 (19.5) 57.27  1.46 34.6 10.33  0.52 15.96  0.71
Other infection 37 (6.9) 54.32  2.53 51.4 9.11  0.88 14.24  0.96
Suicide 35 (6.6) 49.05  1.76 28.6 5.12  0.76 8.68  0.93
Cancer 18 (3.4) 65.06  2.13 27.8 7.53  1.14 14.18  1.44
Stroke 14 (2.6) 62.73  3.55 35.7 7.50  1.32 14.29  1.72
Trauma 5 (0.9) 54.00  5.39 20.0 5.00  1.84 10.20  3.15
Other 194 (36.4) 58.60  0.93 43.8 9.02  0.33 13.11  0.44
Unknown 126 (23.6) 57.83  1.16 52.4 9.48  0.39 13.42  0.50
Places of death
Hospital 152 (29.8) 57.83  1.19 32.2 8.48  0.37 13.08  0.52
Home 122 (23.9) 56.32  1.21 49.2 8.23  0.48 12.72  0.58
Nursing home 101 (19.8) 59.70  1.52 47.5 11.01  0.63 15.95  0.86
Hospice care 17 (3.3) 50.88  3.97 35.3 9.13  1.18 13.06  1.38
Unknown 118 (23.1) 57.42  1.84 44.9 8.08  0.66 13.75  0.91
SD, standard deviation.
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Apart from the biological characteristics of HD, such as the
low kinetics of brain degeneration,12 other independent factors
could contribute to our results and justify their variability. Ide-
ally, individual characteristics, such as the number of CAG
repeats, age of onset, sex, and severity of motor, cognitive, and
behavioral phenotype, should have been included in our analy-
sis. Unfortunately, we did not have enough statistical power to
study these characteristics, but we expect this to be possible
with Enroll-HD,13 a prospective, observational, multinational
platform that will include North American, Australian, Latin
American, Asian, and European centers.
When considering REGISTRY, as far as age of onset and
survival are concerned, our results indicate that HD has a dis-
tinctive natural history among neurodegeneration: in contrast to
patients with nonmonogenetic Alzheimer’s disease and Parkin-
son’s disease, patients with HD tend to be diagnosed sooner in
life–between the fourth and fifth decades of life–and to live
longer after motor diagnosis14–17 and after symptoms onset,
although reports on other conditions indicate a large variation
possibly explained by age of onset. A similar analogy may be
applicable to other forms of dementia, such as vascular dementia
and mixed dementia.14,15 These results were unexpectedly
higher than the median survival times previously reported.18–20
We believe this difference could be explained at least in part by
a hypothetical better standard of care of patients who are fol-
lowed at centers belonging to the EHDN. Some evidence sug-
gests that collaboration with clinical and research networks may
positively influence outcomes.21 For the same reason, a draw-
back from our results is that they may not be extrapolated to
patients who are followed outside these networks.
It is noteworthy that the mean ages of diagnosis (49 years)
and death (58 years) were calculated assuming a normal distri-
bution and that the median survival times (35 and 24 years after
symptom onset and the formal diagnosis, respectively) were cal-
culated using a nonparametric distribution. As such, these results
cannot be directly compared.
The patients in this study died most frequently from the
same conditions described in previous studies of HD22–24 and
other neurodegenerative diseases, such as Alzheimer’s disease,
vascular dementia,14,25 and Parkinson’s disease.26 Those studies
demonstrated that pneumonia leads to death 4.7 times more
often in patients who have HD compared with the general
population,27 representing the primary cause of death.22–24,28,29
According to the same studies, other frequent causes of death
were other infectious processes,22,23 suicide,22,29,30 cardiovascu-
lar diseases,22–24,28,29 and nutritional unbalances, such as
cachexia.22,23,29 Strikingly, these 4 conditions seemed to be as
prevalent in patients with HD as they were in the general
population.27
Two seminal studies from the 1980s based on death certifi-
cates in the United States reported on 2 major discrepancies
compared with our results. Haines et al. described a higher fre-
quency of cardiovascular diseases and of HD as a cause of
death,24 and Lanska and colleagues supported the former results
on cardiovascular diseases.22,27 There are reasons to believe that
the overall improvement in cardiovascular primary and
secondary prevention strategies may justify these differences.
We are also convinced that the diagnosis of HD as a cause of
death is an issue of the past, which vanished with the introduc-
tion of more modern death certificate registries.
A great deal of research has been undertaken on suicide and
associated behaviors in HD. Overall, in the general population,
less than 1% of all deaths are caused by suicide31; however, in
the REGISTRY data set, almost 7% of patients with HD com-
mitted suicide, a figure significantly higher than that in previ-
ous reports.22,23 A previous analysis of this database reported
that a high proportion (9.9%) of gene carriers present suicidal
ideation32; whereas, in other data sets, the rate was even higher
after isolating patients who had manifest HD, affecting one-fifth
of the population with early HD.33,34 As in the general popula-
tion35 and in patients with other neurodegenerative diseases
like Parkinson’s disease,36 the frequency of completed suicide
in patients with manifest HD may be less than one-half of the
frequency of suicidal ideation, which is in line with these
results.
Surprisingly, the place of death differed greatly from that of
other patients with dementia (i.e., nursing homes)37,38 and was
comparable to the place of death of cancer patients (at hospital
and at home).37,38 We believe this may reflect the burden of
the disease and the lack of competence and training in nursing
homes to deal with the serious behavioral problems associated
with HD. The possible willingness of HD families to care for
their relatives also cannot be excluded. On the other hand, the
high percentage of hospital deaths should ease tissue contribu-
tions to biobanks—a much-needed offer for advancing research
into better understanding the disease.
Several aspects make REGISTRY an ideal database for
answering our current questions. Because HD is a rare disease,
its phenotype must be studied in large, multicenter, and multi-
national studies to achieve robust results. The 9221 participants,
the 165 study sites, and the 20 countries signed up (although
not all contributed data to our results) to the REGISTRY study
qualify this data set as methodologically satisfactory. The annual
follow-up and the HD-specific scales applied to patients
enrolled in REGISTRY may help mitigate 2 of the major
problems identified when studying advanced-stage HD: the
irregular patient follow-up and the difficulty in quantifying dis-
ease status.39 In addition, the REGISTRY protocol assures that
generated data are of high quality by means of frequent moni-
toring carried out both locally at each site and centrally by
trained monitors.11
Unfortunately, even after taking into account its advantages,
our analysis included large numbers of patients without a spec-
ified cause or place of death. This potentially may lead to an
under-representation of specific causes or places of death. This
is likely to have happened, because the follow-up of patients
with advanced-stage HD rarely takes place in hospitals, where
EHDN sites are usually located, but occur in smaller and
more personalized, continuous, and palliative care units, mak-
ing it difficult to ascertain socially complex details about this
period of life in patients with HD. Also, it was outside our
power and ethical permits to gather this information from
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families of patients who had died. Nevertheless, local EHDN
sites should increase their compliance with this practice in the
future. In addition, very few causes of death were confirmed
by autopsy, which may further decrease the strength of our
conclusions in this regard. Some of these issues would be
solved at least in part by the introduction of a codification
system for causes of death and with the use of electronic death
certificates, a tool currently available in some countries.
Importantly, generating uniform results is complex when using
multinational studies.
In conclusion, our inferences give robustness to the results
derived from previous smaller studies, establishing the overall
survival of 24 years after motor diagnosis and 35 years after
symptom onset, the most frequent cause of death (pneumonia),
and the most important places of death (the hospital and the
patient’s home).
Finally, it would interesting to attempt to validate our find-
ings with data from the COHORT study,40 which included
American and Australian patients, and with the Enroll-HD data
set,13 in which, because of the expected increased statistical
power, more analyses should be feasible.
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